You are here: Industry Insights > Vanda Pharmaceuticals

News List

FDA Approves HETLIOZ for Nighttime Sleep Disturbances in Smith-Magenis Syndrome americanpharmaceuticalreview
December 22, 2020
Vanda Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has approved HETLIOZ® (tasimelteon) capsule and liquid formulations for the treatment of adults and children, respectively, with nighttime sleep disturbances associated with ...
Vanda Receives FDA Approval to Proceed with VSJ-110 for Allergic Conjunctivitis americanpharmaceuticalreview
November 02, 2020
Vanda Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activator VSJ-110 (previously known as ...
Vanda Initiates Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia americanpharmaceuticalreview
April 08, 2020
Vanda Pharmaceuticals announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19.
Vanda Pharmaceuticals Receives CRL from FDA for HETLIOZ® in the Treatment of Jet Lag Disorder americanpharmaceuticalreview
August 20, 2019
Vanda Pharmaceuticals Inc. announced that on August 16 2019, it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) as part of its ongoing review of Vanda's supplemental New Drug Application (sNDA) for ...
Vanda Pharmaceuticals’ Hetlioz Shows Promise for Treating Jet Lag biospace
March 06, 2018
Vanda Pharmaceuticals, Inc., based in Washington, D.C., announced positive results from its JET8 Phase III clinical trial of Hetlioz for jet lag disorder.
Aka-what? Fanapt maker Vanda puts antipsychotic side effect front and center in TV awareness ads fiercepharma
August 15, 2017
Vanda Pharmaceuticals, known for its aggressive awareness push on non-24 disorder, has mounted a new campaign focusing on a schizophrenia medication side effect that's less prevalent in patients taking its own drug Fanapt.